Advaxis (ADXS) – Company Press Releases
-
Ayala Pharmaceuticals Announces Second Quarter 2023 Financial Results and Provides Corporate Update
-
Ayala Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Corporate Update
-
Ayala Pharmaceuticals Announces RINGSIDE Results to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
-
Ayala Pharmaceuticals Announces Continuation of RINGSIDE Phase 2/3 Study in Desmoid Tumors Following Recommendation of Independent Data Monitoring Committee
-
Ayala Pharmaceuticals Reports Financial Results For the Fiscal Year Ended October 31, 2022
-
Advaxis and Ayala Pharmaceuticals Complete Merger
-
Advaxis Updates on the Phase 1 Clinical Trial of ADXS-504 for the Treatment of Early Prostate Cancer
-
Ayala Pharmaceuticals and Advaxis Enter into Merger Agreement
-
Advaxis and Ayala Pharmaceuticals Enter into Merger Agreement
-
Advaxis Reports Third Quarter Ended July 31, 2022 Financial Results and Provides a Business Update
-
Advaxis Updates on the Phase 1 Clinical Trial of ADXS-504 for the Treatment of Early Prostate Cancer
-
Advaxis Reports Second Quarter Ended April 30, 2022 Financial Results and Provides a Business Update
-
Advaxis, Inc. Announces 1-for-80 Reverse Stock Split
-
Advaxis to Present Updated Clinical and Immunogenicity Data from Ongoing Phase 1/2 Trial of ADXS-503 in Metastatic Non-Small-Cell Lung Cancer (NSCLC) and Study Design of ADXS-504 Trial in Early Prosta
-
Advaxis to Present at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting
-
Advaxis Announces Publication of ADXS-PSA Data in The Oncologist
-
Advaxis Reports First Quarter Ended January 31, 2022 Financial Results and Provides a Business Update
-
Advaxis Reports Fiscal Year 2021 Financial Results and Provides a Business Update
-
Advaxis Prices Offering of $5,000,000 of Convertible Redeemable Preferred Stock Through a Private Placement
-
Advaxis Presents Updated Clinical Data from Ongoing Phase 1/2 Trial of ADXS-503 in NSCLC and Upcoming Milestones
-
OTC Markets Group Welcomes Advaxis, Inc. to OTCQX
-
Advaxis Announces Acceptance for Trading on the OTCQX
-
Advaxis to Continue to Explore Additional Options to Maximize Stockholder Value
-
Advaxis Issues Letter to Stockholders Regarding Recent Special Meeting Results
-
Advaxis Issues Letter and Second Video Message to Stockholders Regarding Upcoming Special Meeting
-
Nasdaq Grants Advaxis, Inc. an Extension to December 20, 2021, to Complete Merger Transaction with Biosight, Ltd. and Satisfy Initial Listing Requirements
-
Advaxis, Inc. Issues Letter to Stockholders
-
Leading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending Advaxis Stockholders Vote “FOR” Proposed Merger with Biosight
-
Biosight Encourages Advaxis Stockholders to Vote “FOR” Proposed Merger
-
Advaxis Issues Letter and Video Message to Stockholders Regarding Upcoming Special Meeting
-
Leading Independent Proxy Advisory Firm ISS Recommends Advaxis Stockholders Vote “FOR” the Merger with Biosight
-
Advaxis Reports 3rd Quarter Ended July 31, 2021 Financial Results and Provides a Business Update
-
Nasdaq Grants Advaxis, Inc. an Extension to November 22, 2021, to Regain Compliance with the $1.00 Minimum Bid Price Rule and Complete Merger Transaction with Biosight, Ltd.
-
Advaxis Announces Initiation of Phase 1 Clinical Trial of ADXS-504 for the Treatment of Early Prostate Cancer
-
Advaxis to Present at the Non-Small Cell Lung Cancer Drug Development Summit
-
ADVAXIS ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of ADXS and Encourages Investors to Contact the Firm
-
Advaxis and Biosight Announce Entry into Definitive Merger Agreement
-
Advaxis Reports Second Quarter Ended April 30, 2021 Financial Results and Provides a Business Update
-
Advaxis Presents Updated Clinical Data from Ongoing Phase 1/2 Trial of ADXS-503 in NSCLC at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting
-
Advaxis to Present at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting
-
UPDATE - Advaxis Announces Achievement of Second Milestone Under ADXS-HER2 Licensing Agreement with OS Therapies
-
Advaxis Announces Receipt of Second Milestone Payment Under ADXS-HER2 Licensing Agreement with OS Therapies
-
Advaxis, Inc. Announces $20 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
-
Advaxis Presents Translational Biomarker Data from Ongoing ADXS-503 Phase 1/2 Lung Cancer Trial at the American Associated for Cancer Research (AACR) 2021 Annual Meeting
-
Advaxis Announces Agreement with Columbia University Irving Medical Center to Fund Phase 1 Study of ADXS-504 for the Treatment of Early Prostate Cancer
-
Ascentage Pharma Appoints Renowned Oncologist Dr. David Sidransky, MD, to its Board as an Independent Non-Executive Director
-
Advaxis to Present Corporate Overview at the Benzinga Biotech Small Cap Conference
-
Advaxis Reports First Quarter Ended January 31, 2021 Financial Results and Provides a Business Update
-
Advaxis to Present at the American Association for Cancer Research (AACR) 2021 Annual Meeting
-
Advaxis Reports Fiscal Year 2020 Financial Results and Provides a Business Update
Back to ADXS Stock Lookup
